miR-155 regulative network in FLT3 mutated acute myeloid leukemia

被引:22
|
作者
Salemi, Domenico [1 ]
Cammarata, Giuseppe [2 ]
Agueli, Cecilia [1 ]
Augugliaro, Luigi [3 ]
Corrado, Chiara [5 ]
Bica, Maria Grazia [1 ]
Raimondo, Stefania [5 ]
Marfia, Anna [1 ]
Randazzo, Valentina [1 ]
Dragotto, Paola [1 ]
Di Raimondo, Francesco [4 ]
Alessandro, Riccardo [5 ]
Fabbiano, Francesco [1 ]
Santoro, Alessandra [1 ]
机构
[1] AO Osped Riuniti Villa Sofia Cervello, Div Ematol Con UTMO, Palermo, Italy
[2] IBIM CNR, Palermo, Italy
[3] Univ Palermo, Dipartimento Sci Stat & Matemat Silvio Vianelli, I-90133 Palermo, Italy
[4] PO Ferrarotto Catania, Div Ematol, Catania, Italy
[5] Dipartimento Biopatol & Biotecnol Med & Forensi, Sez Biol & Genet, Palermo, Italy
关键词
Network; MicroRNA; AML; INTERNAL TANDEM DUPLICATION; MICRORNA EXPRESSION PROFILES; TRANSCRIPTION FACTORS; GENE-EXPRESSION; CELL-GROWTH; DIFFERENTIATION; TARGET; IDENTIFICATION; PROLIFERATION; SUPPRESSION;
D O I
10.1016/j.leukres.2015.04.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Acute myeloid leukemia (AML) represents a heterogeneous disorder with recurrent chromosomal alterations and molecular abnormalities. Among AML with normal karyotype (NK-AML) FLT3 activating mutation, internal tandem duplication (FLT3-ITD), is present in about 30% of patients, conferring unfavorable outcome. Our previous data demonstrated specific up-regulation of miR-155 in FLT3-ITD+ AML. miR-155 is known to be directly implicated in normal hematopoiesis and in some pathologies such as myeloid hyperplasia and acute lymphoblastic leukemia. Methods and results: To investigate about the potential influence of miR-155 de-regulation in FLT3-mutated AML we generated a transcription factors regulatory network and combined this with data from multiple sources that predict miR-155 interactions. From these analyses, we derived a sub-network, called "miR-155 module" that describes functional relationship among miR-155 and transcription factorsin FLT3-mutated AML. We found that "miR-155 module" is characterized by the presence of six transcription factors as central hubs: four miR-155 regulators (JUN, RUNX1, FOSb, JUNB) and two targets of miR-155 (SPI1, CEBPB) all known to be "master" genes of myelopoiesis. We found, in FLT3-mutated AML, a significant down-regulation of miR-155 target genes CEBPB and SPI1 and up-regulation of miR-155 regulator genes JUN and RUNX1. We also showed that PKC412-related FLT3 inhibition, in MV4-11 cell line, causes down-regulation of miR-155 and increased level of mRNA and protein of miR-155 target SPI1. We showed in experiments of miR-155 mimic in K562 cell line, a high increase of miR-155 and an inverse correlation with the mRNA levels of its targets SPI1 and CEBPB. Moreover silencing of miR-155 in primary AMLs causes mRNA up-regulation of its target SPI1 and CEBPB. Conclusion: Our results suggest that activating mutation of FLT3 in AML can lead, through the induction of JUN, to an increased expression of miR-155, which then causes down-regulation of SPI1 and CEBPB and consequently may causes block of myeloid differentiation. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:883 / 896
页数:14
相关论文
共 50 条
  • [31] FLT3 Inhibitors in Acute Myeloid Leukemia: An Update
    Stone, R. M.
    ANNALS OF HEMATOLOGY, 2011, 90 : S70 - S72
  • [32] FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA IN CHILDHOOD
    Alonso, Cristina
    Rubio, Patricia
    Gallego, Marta
    Medina, Adriana
    Rossi, Jorge
    Felice, Maria
    PEDIATRIC BLOOD & CANCER, 2011, 57 (05) : 767 - 767
  • [33] Potential targeting of FLT3 acute myeloid leukemia
    Ambinder, Alexander J.
    Levis, Mark
    HAEMATOLOGICA, 2021, 106 (03) : 671 - 681
  • [34] Evaluation of a FLT3 Bite® for Acute Myeloid Leukemia
    Goldstein, Rebecca
    Henn, Anja
    Koppikar, Priya
    Archibeque, Ivonne
    Frank, Brendon
    Balazs, Mercedesz
    Dahlhoff, Christoph
    Raum, Tobias
    Li, Chi-Ming
    Wahl, Joachim
    Rock, Dan
    Thomas, Oliver
    Karbowski, Christine
    Krupka, Christina
    Subklewe, Marion
    Coxon, Angela
    Chapman-Arvedson, Tara
    BLOOD, 2017, 130
  • [35] FLT3 mutational analysis in acute myeloid leukemia
    Gari, Mamdooh
    Abuzenadah, Adel
    Chaudhary, Adeel
    Qahtani, Mohammed
    Al-Sayes, Fatin
    Damanhouri, Ghazi
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2007, 29 : 106 - 106
  • [36] Targeting FLT3 Mutations in Acute Myeloid Leukemia
    El Fakih, Riad
    Rasheed, Walid
    Hawsawi, Yousef
    Alsermani, Maamoun
    Hassanein, Mona
    CELLS, 2018, 7 (01)
  • [37] Importance of PTM of FLT3 in acute myeloid leukemia
    Liu, Jianwei
    Gu, Jianguo
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2024, 56 (08) : 1199 - 1207
  • [38] Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia
    Fathi, Amir Tahmasb
    Arevalo, Mabel
    Gutierrez, Sonia
    Molero, Antonieta
    Sacilotto, Natalia
    Limon, Ana E.
    Faller, Douglas V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] A review of FLT3 inhibitors in acute myeloid leukemia
    Zhao, Jennifer C.
    Agarwal, Sonal
    Ahmad, Hiba
    Amin, Kejal
    Bewersdorf, Jan Philipp
    Zeidan, Amer M.
    BLOOD REVIEWS, 2022, 52
  • [40] The Development of FLT3 Inhibitors in Acute Myeloid Leukemia
    Garcia, Jacqueline S.
    Stone, Richard M.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (04) : 663 - +